Den samlede forekomsten af febril neutropeni var 9% af patienterne behandlet med pegfilgrastim og 18% af patienterne behandlet med filgrastim (forskel på 9%, 95% CI - 16, 8%; - 1, 1%).
The overall rate of febrile neutropenia was 9% of patients treated with pegfilgrastim and 18% of patients treated with filgrastim (difference 9%, 95% CI of -16.8%, -1.1%).